Author:
Kearney Laura,Wright Paul,Fhadil Sadeer,Thomas Martin, , , ,
Abstract
Postpartum cardiomyopathy (PPCM) is a rare condition that develops near the end of pregnancy or in the months after giving birth, manifesting as heart failure secondary to left ventricular systolic dysfunction. Clinical progression varies considerably, with both end-stage heart failure occurring within days and spontaneous recovery seen. Treatment pathways for heart failure are well established, but the evidence about the safety of medicines passed to infants during breastfeeding is scarce and mainly poor; this often leads to an incorrect decision that a mother should not breastfeed. Given its benefits to both mother and infant, breastfeeding should not routinely be ruled out if the mother is taking heart failure medication but the consequences for the infant need to be considered. An informed risk assessment to minimise potential harm to the infant can be carried out using the evidence that is available along with a consideration of drug properties, adverse effects, paediatric use and pharmacokinetics. In most cases, risks can be managed and infants can be monitored for potential problems. Breastfeeding can be encouraged in women with cardiac dysfunction with PPCM although treatment for the mother takes priority with breastfeeding compatibility being the secondary consideration. International research is continuing to establish efficacy and safety of pharmacotherapy in PPCM.
Reference63 articles.
1. 1. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail 2018;20:951-62. https://doi. org/10.1002/ejhf.1178. PMID:29578284.
2. 2. CardiomyopathyUK. Peripartum cardiomyopathy. 2018. Available at: www.cardiomyopathy.org/peripartum- cardiomyopathy/intro (accessed 25 July 2018).
3. 3. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016;133(14):1397-409. https://doi.org/10.1161/ CIRCULATIONAHA.115.020491. PMID:27045128.
4. 4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016;37(27):2129-200. https://doi. org/10.1093/eurheartj/ehw128. PMID:27206819.
5. 5. Sliwa K, Mebazaa A, Hilfiker-Kleiner D et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 2017;19:1131-41. https://doi. org/10.1002/ejhf.780. PMID:28271625.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献